Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 12, 2026

Angiodynamics Inc (ANGO)

A forensic read on Angiodynamics Inc built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

D · Weak — demands caution

Forensic grade

Grey Zone

Financial health

2.6

Distress distance

Clean

Earnings quality

Forensic signals

-17.8

P / E (ttm)

-21.5%

ROE

$651M

Market cap

0.00%

Dividend yield

9.5%

Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Angiodynamics Inc earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 2.6, placing it in the Grey zone. 4 forensic signals were flagged in its latest SEC filings, led by return on invested capital.

What the filings flag

-22.8%

FY2026

Return on invested capital. Return on invested capital is -22.8% in the latest fiscal year and slipping from -10% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.

+1.7%/yr

FY2023–FY2026

Share-count dilution. Diluted share count changed +5% over the last 3 years to FY2026 (+1.7%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~1.7% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2023 has been diluted ~5%.

stopped

FY2025→FY2026

Shareholder returns — halted. Capital returns have STOPPED — $2M of buybacks + dividends in FY2025, but ~$0 in FY2026. A halt usually means the company is conserving cash.

$333M

FY2020–FY2024

Goodwill impairments. Took $333M of goodwill writedowns across 3 years (FY2020 ($159M), FY2023 ($15M), FY2024 ($159M)). Writedowns mean past acquisitions underperformed what was paid for them.

Key fundamentals

Latest Revenue$320.2M

Revenue Growth YoY+9.5%

Revenue CAGR (3yr)-1.9%

Net Margin-11.5%

Free Cash Flow$508,000.00

Return on Equity-21.5%

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Angiodynamics Inc's actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Aug 12, 2026. Forensic signals flag probability, not certainty.